Pfizer Inc. (PFE) Holdings Raised by Van Hulzen Asset Management LLC

Van Hulzen Asset Management LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 5.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 91,224 shares of the biopharmaceutical company’s stock after purchasing an additional 5,055 shares during the period. Van Hulzen Asset Management LLC’s holdings in Pfizer were worth $3,257,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of PFE. LVM Capital Management Ltd. MI grew its position in Pfizer by 0.5% in the 2nd quarter. LVM Capital Management Ltd. MI now owns 276,198 shares of the biopharmaceutical company’s stock worth $9,277,000 after purchasing an additional 1,425 shares in the last quarter. D. Scott Neal Inc. grew its position in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Cascade Investment Advisors Inc. grew its position in Pfizer by 89.1% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,200 shares in the last quarter. Winslow Evans & Crocker Inc. grew its position in Pfizer by 22.4% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 58,507 shares of the biopharmaceutical company’s stock worth $1,969,000 after purchasing an additional 10,709 shares in the last quarter. Finally, Legacy Private Trust Co. grew its position in Pfizer by 3.8% in the 2nd quarter. Legacy Private Trust Co. now owns 59,082 shares of the biopharmaceutical company’s stock worth $1,984,000 after purchasing an additional 2,150 shares in the last quarter. 69.87% of the stock is owned by institutional investors and hedge funds.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

Shares of Pfizer Inc. (NYSE:PFE) opened at $34.16 on Friday. The company has a market cap of $206,830.00, a P/E ratio of 9.70, a P/E/G ratio of 1.98 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a 52 week low of $31.67 and a 52 week high of $39.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. Pfizer’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.47 EPS. research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer announced that its board has initiated a stock buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.98%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is presently 38.64%.

A number of research analysts have weighed in on PFE shares. BMO Capital Markets set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, February 5th. Barclays boosted their target price on shares of Pfizer from $38.00 to $41.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Credit Suisse Group boosted their target price on shares of Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, January 31st. Leerink Swann boosted their target price on shares of Pfizer from $35.00 to $38.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. Finally, UBS Group set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $39.45.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2018/02/10/pfizer-inc-pfe-holdings-raised-by-van-hulzen-asset-management-llc.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply